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ISPOR CODE OF ETHICS
PREAMBLE
ISPOR expects itself and its members to adhere to the highest ethical standards 
because the Society recognizes that its activities and those of its members affect a
number of constituencies. These include but are not limited to:
 ▶ Patients who are ultimately going to experience the greatest impact of the 
 research.
 ▶ Health care professionals who will be treating or not treating patients with 
 therapies, medications and procedures made available or not made available 
because of the research.
 ▶ Decision-Makers and Payers who must decide what is covered so as to  opti-
mize the health of the patient and resource utilization. This includes:
 { Government Groups who require the results of research to set policy and 
prices.
 { Insurers who base health care coverage and/or payment decisions on the 
 research.
 { Employers where the research affects their decisions on providing health 
beneﬁts.
 { Administrators and Others such as U.S. managed care personnel who need 
 results that are both practical and useful.
 ▶ Outcomes Researchers.
 ▶ Pharmaceutical Manufacturers whose products are often the subject or fo-
cus of the research.
 ▶ Colleagues, where relationships in conducting research and related activities 
are particularly critical.
 ▶ Research employees concerned about how they are regarded, compensated 
and treated by the researchers for whom they work
 ▶ Students who work for researchers, where respect and lack of exploitation are 
important. They are the future of the profession.
 ▶ Clients for whom the research is conducted and the researchers’ relationships 
with them.
The main objective of the Code is to help the science of pharmacoeconomics and 
outcomes research avoid or otherwise deal with credibility challenges based on 
methods or bias concerns, through behaviors and practices intended to insure that 
this research is designed, conducted, and reported in the most proper and ethical 
way possible. By accomplishing this, the various affected constituencies will be able 
to trust and beneﬁt from research ﬁndings as much as possible. The Code also 
includes some general ethical considerations for the Society.
DESIGN AND RESEARCH PRACTICES
1. Members should maintain a current knowledge of research practices, with 
due consideration of those practices most relevant to the research that is 
being done in their own countries.
2. Members should adhere to the standards of practice for their respective 
ﬁelds of research and identify any ofﬁcial Guidelines/Standards used. 
3. Members’ research designs should be deﬁned a priori, reported trans-
parently, defended relative to alternatives, and planned to recognize and 
minimize all types of bias.
4. Members should respect the rights of research subjects in designing and 
 conducting studies.
5. Members should respect the reputations and rights of colleagues when 
engaged in collaborative projects.
6. Members should maintain and protect the integrity of the data used in their 
 studies.
7. Members should not draw conclusions beyond or inconsistent with what 
their data would support.
SPONSORSHIP
8. Members should fully disclose the identity of sponsors of their research.
9. Members should strive to avoid bias and the appearance of bias in con-
ducting research, such as in the choice of methods and data inputs, or in 
the selective reporting of results.
10. Members should be aware of conﬂicts of interest and the appearance of 
conﬂicts of interest. As a point of reference, members should look to the 
rules on disclosure of interest laid down by major peer reviewed journals.
11. Members should maintain their professional autonomy and objectivity in 
conducting and reporting, in writing or verbally, research ﬁndings.
PUBLICATION AND DISSEMINATION
12. Members should endeavor to publicly disseminate their work, and to pub-
lish it in peer reviewed journals when possible.
13. Members should discourage, where possible, listing of an author on any 
publication where the individual has not performed substantial work. As 
a point of reference, members should look to the checklists provided 
by major peer reviewed journals to assist them in deciding inclusion of 
authors.
14. Members should seek to establish, in advance, a clear agreement on 
whether the results of a given piece of work could be published. This 
could include statements on whether the sponsor has a right to review or 
approve any manuscript prior to publication. Considerations could include 
revelations of safety issues.
15. Members should respect contractual rights when they agree to perform 
work for hire and should refrain from disseminating information which they 
agreed in advance to keep proprietary.
16. Methods sections of papers should give thorough, transparent attention 
to all measures taken to minimize bias.
17. Methods sections of papers should identify and justify all departures from 
the a priori analysis plan.
18. Members should work with editors of journals and other publications to 
encourage the establishment and/or maintenance of an appropriate peer 
review process that examines the quality of the methodological rigor inde-
pendently of the institution for which the individual works.
19. Any contributor to a report or publication should disclose any current or 
past relationships with a company or competitor of any product discussed 
in the work.
RELATIONSHIPS WITH OTHERS
20. Members should treat their research employees with respect and should 
compensate them fairly for their work.
21. Members should protect and promote the interests of their employers, 
provide competent work, adhering to these broader guidelines, and 
 protect proprietary information.
22. Members should treat students with respect and refrain from exploiting 
them under any circumstances.
23. Members should provide competent, honest and objective work for cli-
ents, adhering at all times to relevant standards of conduct for conducting 
and reporting research.
ROLE OF ISPOR
24. ISPOR should publicize this Code of Ethics to members and non-members 
involved in pharmacoeconomics and outcomes research.
25. ISPOR should strive for a balance in sponsorship of its conferences 
and other activities, thereby avoiding the appearance of bias or conﬂict 
of interest.
26. Because, as a practical matter, most funding will come from commercial 
interests, ISPOR should continue to maintain its own statement of objectivity 
and autonomy from sponsors.
27. ISPOR should strive to assure that its journal, Value in Health, only pub-
lishes papers that have gone through a rigorous peer- review process.
28. As much as is possible, ISPOR should have a Board of Directors that is 
representative of the various constituencies the Society serves.
29. Similarly, to the extent that it is feasible, the ISPOR program planning and 
selection committees should have membership representative of all of its 
major constituencies.
30. Like other professional societies, ISPOR should be conscious of broader 
ethical issues impacting on global and regional medical resource alloca-
tion, public health policies and the global healthcare environment. These 
issues include but are not limited to: prejudice, equity in healthcare deliv-
ery and access. ISPOR should encourage researchers to utilize opportuni-
ties in their activities and work to address these issues.
